| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
|
Mizugaki, Hidenori
|
|
2015
|
76 |
5 |
p. 1063-1072
|
artikel
|
| 2 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
|
Mikhail, Sameh
|
|
|
76 |
5 |
p. 1005-1012
|
artikel
|
| 3 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
|
Mikhail, Sameh
|
|
2015
|
76 |
5 |
p. 1005-1012
|
artikel
|
| 4 |
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer
|
Lee, Hyo-Sun
|
|
2015
|
76 |
5 |
p. 933-937
|
artikel
|
| 5 |
Erratum to: Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1
|
Wei, Liu
|
|
2015
|
76 |
5 |
p. 1099
|
artikel
|
| 6 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)
|
You, Benoit
|
|
2015
|
76 |
5 |
p. 939-948
|
artikel
|
| 7 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89)
|
Shkalim-Zemer, Vered
|
|
2015
|
76 |
5 |
p. 909-916
|
artikel
|
| 8 |
Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors
|
Damaraju, Vijaya L.
|
|
2015
|
76 |
5 |
p. 1093-1098
|
artikel
|
| 9 |
Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype
|
Lopus, Manu
|
|
2015
|
76 |
5 |
p. 1013-1024
|
artikel
|
| 10 |
Personalizing chemotherapy dosing using pharmacological methods
|
Patel, Jai N.
|
|
2015
|
76 |
5 |
p. 879-896
|
artikel
|
| 11 |
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial
|
Morgan, Robert J.
|
|
2015
|
76 |
5 |
p. 897-907
|
artikel
|
| 12 |
Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations
|
Queckenberg, Christian
|
|
2015
|
76 |
5 |
p. 1081-1091
|
artikel
|
| 13 |
Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
|
Tan, Antoinette R.
|
|
2015
|
76 |
5 |
p. 1051-1061
|
artikel
|
| 14 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)
|
Allendorf, Daniel J.
|
|
2015
|
76 |
5 |
p. 949-955
|
artikel
|
| 15 |
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
|
Yamazaki, N.
|
|
2015
|
76 |
5 |
p. 997-1004
|
artikel
|
| 16 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
|
Gabrielson, Andrew
|
|
2015
|
76 |
5 |
p. 1073-1079
|
artikel
|
| 17 |
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
|
Yamazaki, N.
|
|
2015
|
76 |
5 |
p. 969-975
|
artikel
|
| 18 |
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
|
Bendell, Johanna C.
|
|
2015
|
76 |
5 |
p. 925-932
|
artikel
|
| 19 |
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors
|
Han, Kelong
|
|
2015
|
76 |
5 |
p. 917-924
|
artikel
|
| 20 |
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
|
Bulten, Ben F.
|
|
2015
|
76 |
5 |
p. 957-967
|
artikel
|
| 21 |
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters
|
Ajgal, Zahra
|
|
2015
|
76 |
5 |
p. 1033-1039
|
artikel
|
| 22 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
|
Tolcher, Anthony W.
|
|
2015
|
76 |
5 |
p. 1025-1032
|
artikel
|
| 23 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
|
Tolcher, Anthony W.
|
|
2015
|
76 |
5 |
p. 1041-1049
|
artikel
|
| 24 |
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
|
Zhang, Linna
|
|
2015
|
76 |
5 |
p. 977-987
|
artikel
|
| 25 |
Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients
|
Shinke, Haruka
|
|
2015
|
76 |
5 |
p. 989-996
|
artikel
|
Tijdschrift beschrijving